ReportWire

Tag: rsv

  • Flu cases surge in New York this holiday season | Long Island Business News

    [ad_1]

    THE BLUEPRINT:

    • hospitalizations jump 75% in one week.

    • is the dominant strain statewide.

    • cases up 35% and COVID cases up 15% across NY.

    • Experts urge flu, RSV, and COVID before holidays

    Medical experts are urging New Yorkers to protect themselves against . Since Thanksgiving, flu especially is hitting the region hard, including on Long Island, where activity level for respiratory illness is “very high,” according to the weekly influenza surveillance report by the U.S. Centers for Disease Control and Prevention.

    “Flu is rising a lot faster than it did last year,” Dr. Dwayne Breining, senior vice president of Lab Services at , said in a news release about the rise in flu, respiratory syncytial virus (RSV) and COVID.

    According to the most recent statewide figures, 1,399 people were hospitalized with the flu during the week ending Dec. 6, marking a 75% increase from 798 hospitalizations reported the previous week.

    Breining anticipates that this will be an active flu season for the third straight year.

    “That’s driven by a couple of factors: There aren’t as many people getting vaccinated. There’s a lot of misinformation about vaccines out there. The other thing: The virus continues to mutate,” he said.

    Currently, influenza A is the main flu virus spreading in New York State. Among the flu A cases that have been tested this season, about 94% are the H3 type, according to state data.

    Flu seasons often don’t peak until around February, so it’s too early to know how big a problem that mismatch will be.

    Hospitalized flu cases at Northwell are evenly split between children and older adults, said Dr. Annemarie Stroustrup, senior vice president of Pediatric Services at Northwell, which oversees Cohen Children’s Medical Center. The children’s hospital is already at capacity.

    And across the state, RSV cases are up 35 percent while COVID is up 15 percent, according to state data.

    Medical experts say vaccines are available to protect against flu, COVID and RSV, ahead of holiday gatherings and travel.

    “We expect a more severe flu season due to circulating strains of the virus compared to last year,” State Commissioner Dr. James McDonald said in a written statement.

    “To protect yourself and loved ones against COVID, influenza and RSV, we strongly encourage you to take action for your health and get vaccinated ahead of the holidays,” he said. “Gathering with loved ones is what this season is all about. Vaccines ensure we have the best protection.”

     


    [ad_2]

    Adina Genn

    Source link

  • Feeling the flu: Doctors see simultaneous uptick in flu and RSV cases – WTOP News

    [ad_1]

    Local emergency rooms are seeing a rise in flu and respiratory syncytial virus cases at the same time, an uncommon trend. 

    Local emergency rooms are seeing a rise in flu and respiratory syncytial virus cases at the same time, an uncommon trend.

    Respiratory syncytial virus, better known as RSV, tends to peak when the flu season starts to trend down.

    That’s not the case this year — the viruses are peaking simultaneously.

    Jon Gonella, a physician assistant at MedStar Health, said no one was caught off guard.

    “We’re not surprised to see them,” said Gonella. “We fully expect to see them.”

    To avoid that flu fever or RSV cough, Gonella said it’s best to go back to the basics.

    “Good hand hygiene,” he said. “I know we talk about it a lot. But it really does make a difference.”

    The CDC also recommends getting vaccinated and staying home when you feel sick.

    While the flu and RSV see an upward tick in cases, there’s one respiratory illness that hasn’t shown up as much this year.

    “Not a lot of COVID,” Gonella said.

    The Centers for Disease Control ranked COVID-19 as “very low” nationwide and “growing” in the D.C. area.

    Get breaking news and daily headlines delivered to your email inbox by signing up here.

    © 2025 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

    [ad_2]

    Gigi Barnett

    Source link

  • ‘We have to protect the whole village’: Doctors warn parents as RSV season begins – WTOP News

    [ad_1]

    As cooler weather arrives, so does a rise in seasonal illnesses. One in particular is drawing concern from health experts for its impact on young children.

    As cooler weather arrives, so does a rise in seasonal illnesses. One in particular is drawing concern from health experts for its impact on young children.

    “RSV peak season is upon us,” said Dr. Juanita Mora, an allergist, immunologist and National Medical spokesperson for the American Lung Association.

    Cases of RSV, or respiratory syncytial virus, typically spike from October through March and the illness is especially dangerous for infants and toddlers.

    “One out of every two babies who gets RSV will be hospitalized,” Mora said.

    That troubling statistic is why doctors are urging parents to take steps to protect their children from the highly contagious virus. RSV can cause severe respiratory issues in infants, whose lungs are still developing.

    “A baby can’t handle all the phlegm that’s being produced by this virus as it hits their lungs,” Mora explained. “It causes them to have trouble breathing, and they start using their little muscles in the chest to try to breathe, and their neck as well, too.”

    Parents should be alert to early signs of RSV, which often resemble a common cold but can quickly escalate.

    “One is shortness of breath or wheezing,” Mora said. “The other is signs and symptoms of dehydration.”

    Fatigue, fewer wet diapers and poor feeding are also red flags that a child may need medical attention.

    There are now tools to help protect infants from RSV.

    “There are two ways to protect these babies: one is by giving the RSV vaccine to pregnant moms, the other is by giving a monoclonal antibody shot to babies from birth to eight months,” she said.

    The vaccine for moms is administered between 32 and 36 weeks of pregnancy, passing immunity to the baby for the first six months of life. The monoclonal antibody shot offers direct protection to infants, and is also recommended for high-risk children up to 19 months old.

    Mora said that prevention doesn’t stop with babies and parents, emphasizing that it should extend to grandparents and caregivers.

    “An RSV vaccine also exists to basically protect those greater than 65 years and over,” she said. “So we have to protect the whole village.”

    Health officials also recommend frequent handwashing, masking when sick and keeping ill children home from day care or school to help reduce the spread of RSV.

    Get breaking news and daily headlines delivered to your email inbox by signing up here.

    © 2025 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

    [ad_2]

    Mike Murillo

    Source link

  • Montgomery Co. health officer stresses importance of flu shots for personal, community protection – WTOP News

    [ad_1]

    The Centers for Disease Control is recommending flu shots for everyone 6 months and older as flu season approaches.

    The Centers for Disease Control is recommending flu shots for everyone 6 months and older as flu season approaches.

    According to the CDC, the 2025-26 fall and winter season for illnesses like influenza, RSV and COVID-19 starts in October and runs through mid-May.

    Dr. Kisha Davis, the Montgomery County Health Officer, explains that the benefit of getting a flu shot is twofold: “So there’s the benefit to the individual, of decreasing the chance of getting the flu. … There’s also the benefit to the community. So when more people are vaccinated, it’s harder for that virus or illness or whatever the vaccine is for, to jump to other people.”

    “That’s why we encourage folks to get the flu vaccine, both to help themselves, but also to help community spread,” Davis added.

    She said that’s especially important for older citizens, immunocompromised people and infants who are too young to vaccinate.

    Florida recently elected to eliminate all childhood vaccine mandates, making it the first state to do so.

    “I will say that it’s concerning to see what Florida is doing in terms of rolling back vaccine mandates,” Davis said.

    Noting the high rates of vaccination among residents in the District, Maryland and Virginia, she said, “I do not anticipate that there will be a rollback because of the evidence we have seen” on the effectiveness of vaccine mandates.

    Davis said measles cases provide a good example of the protections of vaccine mandates.

    “In Maryland, we have a vaccine mandate that kids who are going to school need to have that vaccine,” she said.

    When there have been isolated cases of measles, mostly from people who have traveled abroad, “it hasn’t spread and that’s because the vaccine rates are so high in this area. And so we know that those mandates work,” she said.

    Asked about coverage for the different vaccines for respiratory illnesses, Davis said, “For flu vaccine, we feel pretty comfortable that insurance companies will continue to cover it,”

    But when it comes to COVID-19 vaccines, “the question is around the COVID vaccine and other vaccines where we haven’t gotten that clear guidance from (the Advisory Committee on Immunization Practices) what insurers will do in terms of coverage,” Davis said.

    The Advisory Committee on Immunization Practices is scheduled to meet on Sept. 18.

    Get breaking news and daily headlines delivered to your email inbox by signing up here.

    © 2025 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

    [ad_2]

    Kate Ryan

    Source link

  • CDC’s new acting director Jim O’Neill faces looming decisions on vaccines

    [ad_1]

    The Centers for Disease Control and Prevention is at a crossroads. Last week, CDC Director Susan Monarez was ousted less than a month into her tenure after resisting Secretary Robert F. Kennedy Jr.’s push to align with his vaccine policy agenda. Within hours, three senior leaders — including the chief medical officer and the heads of vaccine safety and respiratory infections — resigned in protest. Their exits capped weeks of mounting tension: biased scientific reviews, the withdrawal of key documents, and a shooting at CDC headquarters tied to COVID misinformation. Hundreds of staff publicly applauded the departing scientists in a rare “clap-out.” 

    Into that vacuum stepped Jim O’Neill, deputy secretary of Health and Human Services, now installed as acting CDC director.

    O’Neill’s résumé breaks sharply with CDC tradition. A Bush-era HHS official turned Silicon Valley investor, he is neither a physician nor a scientist — an unusual profile for the agency’s top post. He is expected to retain his deputy role at HHS while leading the CDC. After his early government service, O’Neill spent nearly two decades in close partnership with billionaire Peter Thiel, managing his funds, directing the Thiel Foundation, and co-founding the Thiel Fellowship. He also led the SENS Research Foundation, a nonprofit focused on anti-aging science. In June, he returned to Washington as deputy secretary; he now holds that position alongside his role as CDC director.

    Health and Human Services Secretary Robert F. Kennedy, Jr., right, conducts the swearing-in ceremony of Jim O’Neill as deputy secretary on June 9, 2025, in Washington, D.C. 

    Department of Health and Human Services via AP


    Former colleagues on both sides of the aisle describe him as smart and diligent, with a deep knowledge of HHS mechanics. They also note his libertarian streak, which could align him well with Secretary Kennedy but set him at odds with school vaccination requirements. His most controversial stance, voiced in 2014, was that the FDA should approve drugs once proven safe, leaving effectiveness to be determined in the marketplace — a proposal widely criticized by public health experts as dangerous.

    O’Neill insists he is “very strongly pro-vaccine,” but his recent post on social media — asking if “omicron is the best vaccine” and suggesting CDC could “redefine the word vaccine at will” — sparked new concerns about his grasp of vaccine science. Experts counter that infection is not the same as vaccination, which confers protection without the risks of acute illness or long COVID.

    He could wear both hats for some time. The White House and Kennedy appear eager to avoid a bruising Senate confirmation fight. Until COVID, the CDC director was not a Senate-confirmed position; Republicans changed that in the pandemic’s aftermath. Leaving O’Neill in an “acting” role could paralyze major decision-making at the agency for the foreseeable future.

    Meanwhile, the CDC’s vaccine advisory committee — made up of all new Kennedy appointees — is preparing for a pivotal September meeting. On the agenda: the newborn hepatitis B dose, infant RSV protection, COVID vaccination for healthy children and young adults, and the combined measles-mumps-rubella-varicella shot. Revisiting so many long-standing childhood immunizations at once would be unprecedented. If recommendations are weakened, Medicaid, the Children’s Health Insurance Program and the Vaccines for Children program could restrict coverage, creating new barriers for families.

    The stakes for CDC are profound. O’Neill has promised to “refocus CDC on infectious disease” and “restore trust,” yet staff and state partners say politicized decisions and budget cuts are already eroding core work. 

    The September vaccine advisory meeting will be the first real test for O’Neill. If he restores scientific processes, including transparent reviews, expert briefings, and evidence being vetted and posted before votes, CDC insiders say he could stabilize morale at the agency and preserve the credibility of its scientifically-based recommendations. If not, the resignations of senior scientists may prove the start of a broader exodus, leaving states and families without clear guidance just as flu, RSV and COVID converge this fall.

    [ad_2]

    Source link

  • 5 parenting practices that have changed since you were a baby

    [ad_1]

    (CNN) — Parenting is not for the faint of heart. It can take new parents a beat or two to fully tune in to what their baby’s cries could mean. So many small but consequential decisions need to be made on a daily, if not hourly, basis. There are also questions. Many questions.

    At a time when misinformation abounds, pediatrician Dr. David Hill is the calm voice of reassurance and reason, grounded in science. He encourages new parents to ask their baby’s pediatrician questions, including about any advice they find on the internet.

    “People come to me with stuff all the time,” Hill said, noting the importance of forging a solid parent-pediatrician relationship. That trust, he said, is what’s “going to steer us through this swamp of misinformation and disinformation that’s out there right now.”

    Hill is a father of five in a blended family who has been in practice for more than 25 years. He has been the associate medical editor of the American Academy of Pediatrics’ book “Caring for Your Baby and Young Child: Birth to Age 5, 8th edition,” and is slated to be the editor-in-chief for the next edition. He also cohosts the academy’s podcast “Pediatrics On Call.”

    “The question I get the most often from new parents, and even those who have been at it for a while is, is this normal?” Hill told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently on his podcast, Chasing Life.

    “As somebody who’s seen probably over 10,000 children … it is a joy for me to almost always be able to reassure, and be like, ‘Yeah. That’s fine. They do that. Kids do a lot of weird things, and they do a lot of things at their own pace,” Hill said. “Normal can be all over the map.”

    You can listen to the podcast’s full episode here.

    Hill said he strongly urges parents to seek out trusted, reliable sources for guidance. “Sources of information that have been validated, that use real data,” he said. “And honestly, talk to your child’s doctor — develop that relationship, because that’s what we’ve dedicated our lives to doing.”

    Hill works closely with the AAP on the organization’s parent-facing information. “I do that because I know, over decades of experience, how dedicated everybody in that group is to making sure we get this right, including being willing to get egg on our faces and say, ‘You know what? We were wrong,’ when we were wrong,” Hill said. “And that’s really critical. Anybody who’s never wrong, I don’t trust, because none of us is perfect.”

    During the decades Hill has been in practice, he has witnessed some of the babies he saw at the start of his career become parents themselves. During that time, he has also watched the science of child health evolve.

    “What I tell these new parents is sometimes the complete opposite of what I said when they were babies!” he said via email.

    Here are the five biggest changes Hill has seen over his career.

    Safe sleep practices

    Sleep guidelines literally flipped in 1994, when Hill finished medical school. That year, the National Institute of Child Health and Human Development launched the first “Back to Sleep” campaign urging parents to put their baby to sleep on their back. Before then, parents had been told to put an infant to sleep on the belly to avoid aspiration.

    But that’s not all. The US Consumer Product Safety Commission banned drop-side cribs from the marketplace in 2011 and warned against inclined sleepers in 2019, Hill said. And the Safe Sleep for Babies Act, signed into federal law in 2022, outright banned the sale of drop-side cribs and crib bumpers that could potentially suffocate infants.

    He noted that in 1990, there were 154 sudden unexpected infant deaths per 100,000 babies, a number that fell 44% to a low of 86 in 2011. (It has since gone up to 100 deaths per 100,000 in 2022).

    “While some of those deaths are from mysterious or unavoidable causes,” he said, “many could still be prevented by following all the safe sleep guidelines, including not only placing infants on their backs to sleep, but never co-sleeping (and) avoiding soft bedding.”

    Advice to prevent food allergies

    Complete avoidance is out, and small exposures are in.

    “I still remember in 2015 searching all the drawers in our practice for outdated infant feeding handouts that, if parents followed them, could put their babies at increased risk of developing life-threatening food allergies,” Hill said. “These handouts told parents to avoid giving their infants and toddlers anything containing peanuts or eggs until they turned at least 2 years old, even 3 if they had eczema or a family history of allergies.”

    But, Hill said, in 2015, the results of the LEAP trial confirmed what some earlier studies had suggested: “That it wasn’t early peanut exposure that had caused a doubling of peanut allergies in the preceding decade. It was the advice in these handouts!” he said.

    Now parents and guardians are advised to introduce peanut-containing products and eggs along with other solid foods in the first year of life, as soon as babies are safely taking solids, usually around 6 months of age.

    Preventing babies from having any exposure to potential allergens apparently left their immune systems oversensitive when they finally did encounter them later on.

    Umbilical cord care

    Umbilical cords used to be treated with a messy (for doctors) purple “triple” dye — an antiseptic to keep bacterial infections at bay. Now, the recommendation in well-resourced countries and communities is to let the cord dry on its own — and to keep a close eye on it.

    “The purpose of the dye was to prevent potentially dangerous infections of the umbilical cord and surrounding tissues (omphalitis),” Hill said. “Then, a few brave souls, perhaps fed up with their dry-cleaning bills, decided to see what would happen if we used alcohol instead of the dye. It turned out … nothing.”

    Hill said the next step was to just let the cord dry on its own, taking care not to trap it in a wet or soiled diaper for extended periods and to avoid soaking it at bathtime. That practice is where the guidance stands today.

    Some known risk factors for omphalitis, Hill said, include low birth weight, prolonged rupture of membranes or prolonged labor, maternal infection, nonsterile delivery or home birth, and improper cord care.

    “If you see the skin around the belly button turning red or notice an unusually foul discharge, get your baby seen,” he advised.

    What about bathing? Should new parents avoid baths until the cord falls off? “Advice on this one varies, but it’s not clear there’s any more danger from a brief immersion than from a sponge bath,” he said.

    New and better vaccines

    The vaccination schedule for infants and children has been updated throughout the years as new shots become available, offering better protection against childhood scourges.

    “My dad is also a pediatrician, and I grew up hearing horror stories of babies suffering from meningitis and sepsis. It seems my dad was always dashing off to the hospital to perform spinal taps,” Hill recalled. “This started to change, however, in 1985, when a vaccine against Haemophilus influenza B, one of the most dreaded infections of childhood, came out.

    “In training and early in my career, I saw awful infections from another bacteria, pneumococcal pneumonia. These infections became much rarer in 2000, when the first pneumococcal vaccine for children came out,” he said. “Since then, that vaccine has expanded from covering seven subtypes of pneumococcus to covering as many as 23.”

    Just in the past year, Hill said he witnessed another infantile infection he dreaded, RSV, or respiratory syncytial virus, plummet in frequency and severity thanks to both vaccines for expectant mothers and antibody injections for babies.

    Considering the big picture

    Another change involves a paradigm shift in the way pediatricians think about health and well-being, Hill said.

    “In pediatrics, one of those tectonic shifts hit in 1998, the year I started practice and the year the ACEs Study came out,” he said, referring to a study that looked at adverse childhood experiences. Those potentially traumatic events include physical, emotional and/or sexual abuse; the death of a parent; mental illness; or violence or substance abuse in the household, any of which can create toxic stress in a child, leading to changes in brain development and affecting future mental, physical and emotional health.

    “Many people had noticed that traumatic events in childhood … seemed to impact later health,” Hill said. “The ACEs Study measured and quantified the extent and duration of these effects, and the results were more dramatic and longer-lasting than anyone had guessed.”

    An explosion of research followed, Hill said, which led to a new approach in pediatrics.

    “Every child faces stressful events, some severe enough to impact their health. But the safe, stable, nurturing relationships that children build with the adults around them can protect them,” he explained. “Understanding these interactions inspires trauma-informed care, an effort to work with families to address the stresses in their lives and to build those emotional connections that can help their children thrive.”

    Under this approach, Hill said, pediatricians pivoted from asking “What’s wrong with you?” to asking “What happened to you, and how can we help?”

    “A key concept here is the ‘good enough parent,’” he said. “No parent is perfect, but perfection is not required to be safe, stable, and nurturing.”

    As a parent himself, Hill said that thought “brings me a sigh of relief.”

    [ad_2]

    Andrea Kane and CNN

    Source link

  • Duke Health lifts visitor restrictions as respiratory illnesses decline

    Duke Health lifts visitor restrictions as respiratory illnesses decline

    [ad_1]

    DURHAM, N.C. (WTVD) — All Duke University Health System hospitals will be removing visitation restrictions starting Tuesday.

    The previous rules limited daytime visitors of surgery patients to no more than two people 12 and older. The hospital system says it put the restrictions in place to protect patients and prevent the spread of the flu, RSV, and COVID-19.

    New visitation rules include:

    – Up to four visitors at a time where space permits; switching is allowed.

    – Visiting hours for inpatient, bone marrow transplant, and ICU units will be 8 a.m. – 9 p.m. daily.

    – Visiting hours for maternity, end of life, emergency department, procedural and perioperative surgical units do not end.

    – Visitors of all ages are allowed in inpatient, maternity, and ambulatory spaces.

    – Visitors must be 18+ in perioperative/surgical/procedural areas.

    Exceptions to visitation rules may be given based on special circumstances.

    Copyright © 2024 WTVD-TV. All Rights Reserved.

    [ad_2]

    WTVD

    Source link

  • WTF Fun Fact 13706 – When was RSV Discovered?

    WTF Fun Fact 13706 – When was RSV Discovered?

    [ad_1]

    In the wake of the COVID pandemic, more and more people are insisting that RSV is yet another new virus. But it isn’t. If you haven’t heard of it before, it’s simply because you were lucky enough never to get it.

    Respiratory Syncytial Virus, commonly known as RSV, has a nuanced history that underscores its impact on global health, particularly in children and the elderly. The disease is notorious for causing respiratory tract infections, ranging from mild cold-like symptoms to severe respiratory distress.

    RSV Discovery and Initial Research

    The discovery of RSV dates back to the late 1950s when it was first isolated from chimpanzees with respiratory illness, hence its initial name, “chimp coryza agent.”

    Shortly after, similar viruses were isolated from children with respiratory infections, confirming the virus’s ability to infect humans and its role in pediatric respiratory diseases.

    The Shift in Understanding

    Initial research focused on RSV as a cause of illness in infants and young children, where it was identified as the leading cause of lower respiratory tract infections, such as bronchiolitis and pneumonia.

    However, over the years, the scope of understanding expanded, recognizing it as a significant cause of respiratory illness in adults, especially the elderly and those with underlying health conditions. This highlighted the virus’s broad impact across age groups.

    Vaccine Development Efforts

    One of the most challenging aspects of RSV history involves vaccine development. In the 1960s, a formalin-inactivated RSV vaccine trial resulted in worsened outcomes upon natural infection, leading to severe disease and, tragically, fatalities in some vaccinated infants.

    This setback significantly impacted future vaccine development strategies and underscored the need for a deeper understanding of RSV immunology.

    Treatment for the disease has evolved, focusing on supportive care and, in some cases, the use of antiviral medications or monoclonal antibodies in high-risk groups.

    Efforts to develop a safe and effective vaccine have continued, with several candidates now in late-stage clinical trials, promising hope for future prevention strategies.

    The Ongoing Challenge of RSV

    RSV remains a significant health challenge globally, with millions of children under five years old hospitalized each year due to related illnesses. The seasonal nature of the disease, with annual epidemics in colder months, underscores the ongoing need for effective prevention and treatment strategies.

    Current research into RSV seeks not only to develop safe and effective vaccines but also to better understand the virus’s transmission dynamics, pathogenesis, and long-term impacts on health.

    As science advances, the hope is to reduce the burden of RSV through improved prevention, early detection, and innovative treatments.

     WTF fun facts

    Source: “Human Respiratory Syncytial Virus” — Encyclopedia of Microbiology

    [ad_2]

    WTF

    Source link

  • Flu Not Going Away In The U.S. – KXL

    Flu Not Going Away In The U.S. – KXL

    [ad_1]

    NEW YORK (AP) — The flu virus is hanging on in the U.S., intensifying in some areas of the country after weeks of an apparent national decline.

    Centers for Disease Control and Prevention data released Friday showed a continued national drop in flu hospitalizations, but other indicators were up — including the number of states with high or very high levels for respiratory illnesses.

    “Nationally, we can say we’ve peaked, but on a regional level it varies,” said the CDC’s Alicia Budd. “A couple of regions haven’t peaked yet.”

    Patient traffic has eased a bit in the Southeast and parts of the West Coast, but flu-like illnesses seem to be proliferating in the Midwest and have even rebounded a bit in some places. Last week, reports were at high levels in 23 states — up from 18 the week before, CDC officials said.

    Flu generally peaks in the U.S. between December and February. National data suggests this season’s peak came around late December, but a second surge is always possible. That’s happened in other flu seasons, with the second peak often — but not always — lower than the first, Budd said.

    So far, the season has been relatively typical, Budd said. According to CDC estimates, since the beginning of October, there have been at least 22 million illnesses, 250,000 hospitalizations, and 15,000 deaths from flu. The agency said 74 children have died of flu.

    COVID-19 illnesses seem to have peaked at around he same time as flu. CDC data indicates coronavirus-caused hospitalizations haven’t hit the same levels they did at the same point during the last three winters. COVID-19 is putting more people in the hospital than flu, CDC data shows.

    The national trends have played out in Chapel Hill, said Dr. David Weber, an infectious diseases expert at the University of North Carolina.

    Weber is also medical director of infection prevention at UNC Medical Center, where about a month ago more than 1O0 of the hospital’s 1,000 beds were filled with people with COVID-19, flu or the respiratory virus RSV.

    That’s not as bad as some previous winters — at one point during the pandemic, 250 beds were filled with COVID-19 patients. But it was bad enough that the hospital had to declare a capacity emergency so that it could temporarily bring some additional beds into use, Weber said.

    Now, about 35 beds are filled with patients suffering from one of those viruses, most of them COVID-19, he added.

    “I think in general it’s been a pretty typical year,” he said, adding that what’s normal has changed to include COVID-19, making everything a little busier than it was before the pandemic.

    More about:

    [ad_2]

    Grant McHill

    Source link

  • Flu cases in some Southern states on the rise, bucking national trend

    Flu cases in some Southern states on the rise, bucking national trend

    [ad_1]

    Flu cases in some Southern states on the rise, bucking national trend – CBS News


    Watch CBS News



    Nationally, the number of flu cases has decreased. But in some Southern states, flu activity is still high, including in Dallas County, Texas, where almost 20% of tests are positive. Omar Villafranca reports.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • Winter Illness This Year Is a Different Kind of Ugly

    Winter Illness This Year Is a Different Kind of Ugly

    [ad_1]

    Earlier this month, Taison Bell walked into the intensive-care unit at UVA Health and discovered that half of the patients under his care could no longer breathe on their own. All of them had been put on ventilators or high-flow oxygen. “It was early 2022 the last time I saw that,” Bell, an infectious-disease and critical-care physician at the hospital, told me—right around the time that the original Omicron variant was ripping through the region and shattering COVID-case records. This time, though, the coronavirus, flu, and RSV were coming together to fill UVA’s wards—“all at the same time,” Bell said.

    Since COVID’s arrival, experts have been fearfully predicting a winter worst: three respiratory-virus epidemics washing over the U.S. at once. Last year, those fears didn’t really play out, Sam Scarpino, an infectious-disease modeler at Northeastern University, told me. But this year, “we’re set up for that to happen,” as RSV, flu, and COVID threaten to crest in near synchrony. The situation is looking grim enough that the CDC released an urgent call last Thursday for more vaccination for all three pathogens—the first time it has struck such a note on seasonal immunizations since the pandemic began.

    Nationwide, health-care systems aren’t yet in crisis mode. Barring an unexpected twist in viral evolution, a repeat of that first terrible Omicron winter seems highly unlikely. Nor is the U.S. necessarily fated for an encore of last year’s horrors, when enormous, early waves of RSV, then flu, slammed the country, filling pediatric emergency departments and ICUs past capacity, to the point where some hospitals began to pitch temporary tents outside to accommodate overflow. On the contrary, more so than any other year since SARS-CoV-2 appeared, our usual respiratory viruses “seem to be kind of getting back to their old patterns” with regard to timing and magnitude, Kathryn Edwards, a vaccine and infectious-disease expert at Vanderbilt University, told me.

    But even so-so seasons of RSV, flu, and SARS-CoV-2 could create catastrophe if piled on top of one another. “It really doesn’t take much for any of these three viruses to tip the scale and strain hospitals,” Debra Houry, the CDC’s chief medical officer, told me. It also—in theory—shouldn’t take much to waylay the potential health-care crisis ahead. For the first time in history, the U.S. is offering vaccines against flu, COVID, and RSV: “We have three opportunities to prevent three different viral infections,” Grace Lee, a pediatrician at Stanford, told me. And yet, Americans have all but ignored the shots being offered to them.

    So far, flu-shot uptake is undershooting last year’s rate. According to recent polls, as many as half of surveyed Americans probably or definitely aren’t planning to get this year’s updated COVID-19 vaccine. RSV shots, approved for older adults in May and for pregnant people in August, have been struggling to get a foothold at all. Distributed to everyone eligible to receive them, this trifecta of shots could keep as many as hundreds of thousands of Americans out of emergency departments and ICUs this year. But that won’t happen if people continue to shirk protection. The specific tragedy of this coming winter will be that any suffering was that much more avoidable.

    Much of the agony of last year’s respiratory season can be chalked up to a terrible combination of timing and intensity. A wave of RSV hit the nation early and hard, peaking in November and leaving hospitals no time to recover before flu—also ahead of schedule—soared toward a December maximum. Children bore the brunt of these onslaughts, after spending years protected from respiratory infections by pandemic mitigations. “When masks came down, infections went up,” Lee told me. Babies and toddlers were falling seriously sick with their first respiratory illnesses—but so were plenty of older kids who had skipped the typical infections of infancy. With the health-care workforce still burnt out and substantially pared down from a pandemic exodus, hospitals ended up overwhelmed. “We just did not have enough capacity to take care of the kids we wanted to be able to take care of,” Lee said. Providers triaged cases over the phone; parents spent hours cradling their sick kids in packed waiting rooms.

    And yet, one of the biggest fears about last year’s season didn’t unfold: waves of RSV, flu, and COVID cresting all at once. COVID’s winter peak didn’t come until January, after RSV and flu had substantially died down. Now, though, RSV is hovering around the high it has maintained for weeks, COVID hospitalizations have been on a slow but steady rise, and influenza, after simmering in near-total quietude, seems to be “really taking off,” Scarpino told me. None of the three viruses has yet approached last season’s highs. But a confluence of all of them would be more than many hospitals could take. Across the country, many emergency departments and ICUs are nearing or at capacity. “We’re treading water okay right now,” Sallie Permar, the chief pediatrician at Weill Cornell Medical Center and NewYork-Presbyterian Hospital, told me. “Add much more, and we’re thrown into a similar situation as last year.”

    That forecast isn’t certain. RSV, which has been dancing around a national peak, could start quickly declining; flu could take its time to reach an apex. COVID, too, remains a wild card: It has not yet settled into a predictable pattern of ebb and flow, and won’t necessarily maintain or exceed its current pace. This season may still be calmer than last, and impacts of these diseases similarly, or even more, spaced out.

    But several experts told me that they think substantial overlap in the coming weeks is a likely scenario. Timing is ripe for spread, with the holiday season in full swing and people rushing through travel hubs on the way to family gatherings. Masking and testing rates remain low, and many people are back to shrugging off symptoms, heading to work or school or social events while potentially still infectious. Nor do the viruses themselves seem to be cutting us a break. Last year’s flu season, for instance, was mostly dominated by a single strain, H3N2. This year, multiple flu strains of different types appear to be on a concomitant rise, making it that much more likely that people will catch some version of the virus, or even multiple versions in quick succession. The health-care workforce is, in many ways, in better shape this year. Staffing shortages aren’t quite as dire, Permar told me, and many experts are better prepared to deal with multiple viruses at once, especially in pediatric care. Kids are also more experienced with these bugs than they were this time last year. But masking is no longer as consistent a fixture in health-care settings as it was even at the start of 2023. And should RSV, flu, and COVID flood communities simultaneously, new issues—including co-infections, which remain poorly understood—could arise. (Other respiratory illnesses are still circulating too.) There’s a lot experts just can’t anticipate: We simply haven’t yet had a year when these three viruses have truly inundated us at once.

    Vaccines, of course, would temper some of the trouble—which is part of the reason the CDC issued its clarion call, Houry told me. But Americans don’t seem terribly interested in getting the shots they’re eligible for. Flu-shot uptake is down across all age groups compared with last year—even among older adults and pregnant people, who are at especially high risk. And although COVID vaccination is bumping along at a comparable pace to 2022, the rates remain “atrocious,” Bell told me, especially among children. RSV vaccines have reached just 17 percent of the population over the age of 60. Among pregnant people, the other group eligible for the vaccines, uptake has been stymied by delays and confusion over whether they qualify. Some of Permar’s pregnant physician colleagues have been turned away from pharmacies, she told me, or been told their shots might not be covered by insurance. “And then some of those same parents have babies who end up in the hospital with RSV,” she said. Infants were also supposed to be able to get a passive form of immunity from monoclonal antibodies. But those drugs have been scarce nationwide, forcing providers to restrict their use to babies at highest risk—yet another way in which actual protection against respiratory disease has fallen short of potential. “There was a lot of excitement and hope that the monoclonal was going to be the answer and that everybody could get it,” Edwards told me. “But then it became very apparent that this just functionally wasn’t going to be able to happen.”

    Last year, at least some of the respiratory-virus misery had become inevitable: After the U.S. dropped pandemic mitigations, pathogens were fated to come roaring back. The early arrivals of RSV and flu (especially on the heels of an intense summer surge of enterovirus and rhinovirus) also left little time for people to prepare. And of course, RSV vaccines weren’t yet around. This year, though, timing has been kinder, immunity stronger, and our arsenal of tools better supplied. High uptake of shots would undoubtedly lower rates of severe disease and curb community spread; it would preserve hospital capacity, and make schools and workplaces and travel hubs safer to move through. Waves of illness would peak lower and contract faster. Some might never unfold at all.

    But so far, we’re collectively squandering our chance to shore up our defense. “It’s like we’re rushing into battle without armor,” Bell told me, even though local officials have been begging people to ready themselves for months. Which all makes this year feel terrible in a different kind of way. Whatever happens in the coming weeks and months will be a worse version of what it could have been—a season of opportunities missed.

    [ad_2]

    Katherine J. Wu

    Source link

  • COVID-19 and flu cases are rising in California. How bad will the holiday uptick be?

    COVID-19 and flu cases are rising in California. How bad will the holiday uptick be?

    [ad_1]

    COVID-19 and flu are rising across California, sparking new warnings from health officials to take precautions as the wider winter holiday season looms.

    The uptick is modest and not wholly unexpected — wintertime surges have been an annual occurrence since the coronavirus first emerged. But experts say lagging uptake of the latest reformulated vaccines has left some populations particularly vulnerable to severe health outcomes that are largely preventable at this point.

    Over the week that ended Dec. 9, 2,449 Californians were newly admitted to hospitals with a coronavirus infection, up 40% over the last month, according to federal data.

    California was considered to have “high” viral illness activity level as of Dec. 9, among the worst designations in the country, the U.S. Centers for Disease Control and Prevention said.

    A color-coded map of the United States
    As of Dec. 9, California was considered to have a “high” level of flu-like illness, which includes viral illnesses such as COVID-19 and respiratory syncytial virus, or RSV.

    (U.S. Centers for Disease Control and Prevention )

    “Respiratory illness activity is rapidly increasing across the United States,” the CDC said in a bulletin Thursday afternoon. “Millions of people may get sick in the next month or two, and low vaccination rates mean more people will get more severe disease. Getting vaccinated now can help prevent hospitalizations and save lives.”

    A rise in viral illness is expected this time of year, but the prevalence of COVID-19 adds a considerable health burden that didn’t exist before the pandemic. COVID-19 remains the primary cause of new respiratory hospitalizations and deaths nationally, causing 1,000 fatalities a week.

    “COVID is still causing the most number of cases, the most number of hospitalizations and the most, unfortunately, number of deaths that we’re seeing week over week,” Dr. Mandy Cohen, director of the CDC, said in an online discussion Tuesday. “So while we all wish we could leave COVID in the rearview mirror, it is still here with us, and so we need to make sure we are continuing to take it very seriously.”

    Cohen last week urged people to take precautions such as getting vaccinated, avoiding people who are sick and staying home when ill, regular hand-washing, improving air ventilation and wearing a mask.

    “And get tested, so you know what you have and you can get treatment,” she said. “Getting tested and treated early can prevent you from getting severely ill, being hospitalized and can potentially save your life.”

    Relatively speaking, COVID-19, flu and another ailment — respiratory syncytial virus, or RSV — aren’t at the heights they were this time last year, when their simultaneous circulation spawned a “tripledemic” that stressed healthcare facilities across the state, especially children’s hospitals.

    Kaiser Permanente Southern California began noticing more COVID-19 illness starting in mid-November, with the rise accelerating after Thanksgiving, said Dr. Nancy Gin, regional medical director of quality and clinical analysis for the health system.

    Coronavirus levels in Los Angeles County wastewater were at 38% of last winter’s peak for the week that ended Dec. 2, the most recent data available. That’s exactly the same as the height seen late this summer, when the region experienced a prolonged uptick in infections.

    The latest figure signals a “medium” level of concern, as defined by L.A. County health officials.

    In the San Francisco Bay Area, coronavirus levels in the San Jose watershed’s sewage have been at a “high” level for weeks.

    Rising viral levels in wastewater is “like the canary in the coal mine,” said Dr. Peter Chin-Hong, a UC San Francisco infectious diseases expert. Higher concentrations could be followed by more illness, potentially severe enough to require hospital care.

    “I’m just worried that it’s going to translate into hospitalizations around Christmastime,” he said.

    Chin-Hong said he’s particularly concerned about seniors who haven’t received their updated vaccinations this autumn. Among Californians ages 65 and older, just 27% have received the latest COVID-19 vaccination that became available in September. Uptake is even lower in Los Angeles County — 21% — but higher in the Bay Area, where it’s around 40% in the most populous counties.

    Seniors who have not gotten the latest vaccine are “the population we’re seeing in the hospital,” Chin-Hong said, and, especially those who are older than 75, “the population that’s dying.” It’s also likely that many of those who are dying aren’t getting anti-COVID drugs in time.

    Flu vaccination rates are slightly lower than they were at this time last year, according to data shared by the CDC. As of early November, 36% of U.S. adults had received their flu shot, compared with 38% at that time last year. And for RSV, just 16% of adults ages 60 and older had received the newly available vaccine as of Dec. 2.

    Alarmed by low vaccination rates, the CDC issued a health advisory on “the urgent need to increase immunization coverage for influenza, COVID-19 and RSV.” The agency asked healthcare providers to strongly urge immunizations, noting that “low vaccination rates, coupled with ongoing increases in national and international respiratory disease activity … could lead to more severe disease and increased healthcare capacity strain in the coming weeks.”

    The CDC recommends virtually everyone ages 6 months and older get the latest flu and COVID-19 vaccinations. Adults ages 60 and older are also eligible to be vaccinated against RSV, which can be especially risky for older people with heart disease. There are two vaccines available for older adults: Abrysvo, made by Pfizer; and Arexvy, made by GSK.

    The CDC also recommends the Abrysvo vaccine for pregnant people and immunizing babies against RSV with an antibody known as nirsevimab, also known by the trademarked name Beyfortus.

    The agency is also urging doctors to recommend antiviral drugs for flu and COVID-19, such as Tamiflu and Paxlovid, for eligible patients. These “antiviral medications are currently underutilized, but are important to treat patients, especially persons at high-risk of progression to severe disease with influenza or COVID-19, including older adults and people with certain underlying medical conditions,” the CDC said.

    Such antiviral drugs “are most effective in reducing the risk of complications when treatment is started as early as possible after symptom onset,” the CDC said.

    So far, hospitals in Southern California and the Bay Area appear to be in fairly stable shape. More people are becoming ill, but so far, many aren’t needing to be hospitalized, Chin-Hong said.

    Kaiser Southern California has been noticing more people ill with COVID-19 in its clinics and urgent care centers, “but they’re not landing in the hospital nearly as much compared to last year, certainly compared to two years ago,” Gin said. “Time will tell if the numbers that we see continue to go up.”

    The health system, which serves 4.8 million members and operates 16 hospitals throughout the region, has observed a bit of a rise in the use of ventilators and intensive care units related to COVID-19, “but it’s certainly nothing dramatic,” Gin said.

    But cases of influenza type A virus nationally “are really shooting up quite a bit. We are seeing that as well,” Gin said.

    As for RSV, levels rose steadily from the end of September through mid-November. In the last few weeks, however, that virus seems to have flattened out at “less than half of what we saw last year at this time, at least by our testing numbers. So that’s a good sign,” Gin said.

    Increasing coronavirus transmission is probably being assisted by waning immunity from past infections and older booster shots.

    Officials are also monitoring the rapid rise of the JN.1 subvariant. Because of its unusually high number of mutations, this subvariant — described as a closely related offshoot of the BA.2.86, or Pirola strain — might be able to more easily infect people who had previously caught an older version of the coronavirus or haven’t yet received an updated shot.

    Nationally, JN.1 is estimated to account for about 21% of coronavirus cases for the two-week period that ended Dec. 9, up from 8% in the prior two-week period. It’s the fastest-growing subvariant being tracked.

    JN.1 is on the ascent while the current most dominant subvariant, HV.1, is declining. A descendant of the XBB subvariants that were dominant over the summer, HV.1 was estimated to account for 30% of coronavirus specimens for the most recent two-week period, down from 32% in the prior comparable period.

    The rise of the new subvariant should encourage people, especially those who are older, to get the new vaccine, as outdated booster shots or natural immunity from past infections may not be protective enough. The new vaccine will replenish antibodies, Chin-Hong said, which will be especially important for at-risk people.

    “Most people have gotten a previous infection, like during the summer, with one of the XBBs,” Chin-Hong said. The rise of JN.1 “just makes the clock tick faster before they’re more susceptible [to another coronavirus infection]. In other words, if the XBBs were the main game in town, you might have had a little bit more time before you would get infected again.”

    The CDC said available vaccines, tests and antiviral medication continue to work well against JN.1.

    [ad_2]

    Rong-Gong Lin II

    Source link

  • Do You Have the Flu, RSV, COVID, or the Common Cold?

    Do You Have the Flu, RSV, COVID, or the Common Cold?

    [ad_1]

    Winter is almost here, and with it may come runny noses, coughing, and congestion. But how do you know if you just have a common cold, or if you have one or more of the three respiratory viruses that make up the “tripledemic” – RSV (respiratory syncytial virus), COVID-19, and influenza?

    [ad_2]

    Source link

  • Sick Season Will Be Worse From Now On

    Sick Season Will Be Worse From Now On

    [ad_1]

    Last fall, when RSV and flu came roaring back from a prolonged and erratic hiatus, and COVID was still killing thousands of Americans each week, many of the United States’ leading infectious-disease experts offered the nation a glimmer of hope. The overwhelm, they predicted, was probably temporary—viruses making up ground they’d lost during the worst of the pandemic. Next year would be better.

    And so far, this year has been better. Some of the most prominent and best-tracked viruses, at least, are behaving less aberrantly than they did the previous autumn. Although neither RSV nor flu is shaping up to be particularly mild this year, says Caitlin Rivers, an epidemiologist at the Johns Hopkins Center for Health Security, both appear to be behaving more within their normal bounds.

    But infections are still nowhere near back to their pre-pandemic norm. They never will be again. Adding another disease—COVID—to winter’s repertoire has meant exactly that: adding another disease, and a pretty horrific one at that, to winter’s repertoire. “The probability that someone gets sick over the course of the winter is now increased,” Rivers told me, “because there is yet another germ to encounter.” The math is simple, even mind-numbingly obvious—a pathogenic n+1 that epidemiologists have seen coming since the pandemic’s earliest days. Now we’re living that reality, and its consequences. “What I’ve told family or friends is, ‘Odds are, people are going to get sick this year,’” Saskia Popescu, an epidemiologist at the University of Maryland School of Medicine, told me.

    Even before the pandemic, winter was a dreaded slog—“the most challenging time for a hospital” in any given year, Popescu said. In typical years, flu hospitalizes an estimated 140,000 to 710,000 people in the United States alone; some years, RSV can add on some 200,000 more. “Our baseline has never been great,” Yvonne Maldonado, a pediatrician at Stanford, told me. “Tens of thousands of people die every year.” In “light” seasons, too, the pileup exacts a tax: In addition to weathering the influx of patients, health-care workers themselves fall sick, straining capacity as demand for care rises. And this time of year, on top of RSV, flu, and COVID, we also have to contend with a maelstrom of other airway viruses—among them, rhinoviruses, parainfluenza viruses, human metapneumovirus, and common-cold coronaviruses. (A small handful of bacteria can cause nasty respiratory illnesses too.) Illnesses not severe enough to land someone in the hospital could still leave them stuck at home for days or weeks on end, recovering or caring for sick kids—or shuffling back to work, still sick and probably contagious, because they can’t afford to take time off.

    To toss any additional respiratory virus into that mess is burdensome; for that virus to be SARS-CoV-2 ups the ante all the more. “This is a more serious pathogen that is also more infectious,” Ajay Sethi, an epidemiologist at the University of Wisconsin at Madison, told me. This year, COVID-19 has so far killed some 80,000 Americans—a lighter toll than in the three years prior, but one that still dwarfs that of the worst flu seasons in the past decade. Globally, the only infectious killer that rivals it in annual-death count is tuberculosis. And last year, a CDC survey found that more than 3 percent of American adults were suffering from long COVID—millions of people in the United States alone.

    With only a few years of data to go on, and COVID-data tracking now spotty at best, it’s hard to quantify just how much worse winters might be from now on. But experts told me they’re keeping an eye on some potentially concerning trends. We’re still rather early in the typical sickness season, but influenza-like illnesses, a catchall tracked by the CDC, have already been on an upward push for weeks. Rivers also pointed to CDC data that track trends in deaths caused by pneumonia, flu, and COVID-19. Even when SARS-CoV-2 has been at its most muted, Rivers said, more people have been dying—especially during the cooler months—than they were at the pre-pandemic baseline. The math of exposure is, again, simple: The more pathogens you encounter, the more likely you are to get sick.

    A larger roster of microbes might also extend the portion of the year when people can expect to fall ill, Rivers told me. Before the pandemic, RSV and flu would usually start to bump up sometime in the fall, before peaking in the winter; if the past few years are any indication, COVID could now surge in the summer, shading into RSV’s autumn rise, before adding to flu’s winter burden, potentially dragging the misery out into spring. “Based on what I know right now, I am considering the season to be longer,” Rivers said.

    With COVID still quite new, the exact specifics of respiratory-virus season will probably continue to change for a good while yet. The population, after all, is still racking up initial encounters with this new coronavirus, and with regularly administered vaccines. Bill Hanage, an epidemiologist at Harvard’s T. H. Chan School of Public Health, told me he suspects that, barring further gargantuan leaps in viral evolution, the disease will continue to slowly mellow out in severity as our collective defenses build; the virus may also pose less of a transmission risk as the period during which people are infectious contracts. But even if the dangers of COVID-19 are lilting toward an asymptote, experts still can’t say for sure where that asymptote might be relative to other diseases such as the flu—or how long it might take for the population to get there. And no matter how much this disease softens, it seems extraordinarily unlikely to ever disappear. For the foreseeable future, “pretty much all years going forward are going to be worse than what we’ve been used to before,” Hanage told me.

    In one sense, this was always where we were going to end up. SARS-CoV-2 spread too quickly and too far to be quashed; it’s now here to stay. If the arithmetic of more pathogens is straightforward, our reaction to that addition could have been too: More disease risk means ratcheting up concern and response. But although a core contingent of Americans might still be more cautious than they were before the pandemic’s start—masking in public, testing before gathering, minding indoor air quality, avoiding others whenever they’re feeling sick—much of the country has readily returned to the pre-COVID mindset.

    When I asked Hanage what precautions worthy of a respiratory disease with a death count roughly twice that of flu’s would look like, he rattled off a familiar list: better access to and uptake of vaccines and antivirals, with the vulnerable prioritized; improved surveillance systems to offer  people at high risk a better sense of local-transmission trends; improved access to tests and paid sick leave. Without those changes, excess disease and death will continue, and “we’re saying we’re going to absorb that into our daily lives,” he said.

    And that is what is happening. This year, for the first time, millions of Americans have access to three lifesaving respiratory-virus vaccines, against flu, COVID, and RSV. Uptake for all three remains sleepy and halting; even the flu shot, the most established, is not performing above its pre-pandemic baseline. “We get used to people getting sick every year,” Maldonado told me. “We get used to things we could probably fix.” The years since COVID arrived set a horrific precedent of death and disease; after that, this season of n+1 sickness might feel like a reprieve. But compare it with a pre-COVID world, and it looks objectively worse. We’re heading toward a new baseline, but it will still have quite a bit in common with the old one: We’re likely to accept it, and all of its horrors, as a matter of course.

    [ad_2]

    Katherine J. Wu

    Source link

  • What you need to know about the new RSV shot for babies

    What you need to know about the new RSV shot for babies

    [ad_1]

    Ahead of the winter respiratory virus season, many parents were relieved the U.S. Food and Drug Administration approved a shot to combat respiratory syncytial virus, or RSV, for infants and toddlers this summer.

    But the shot is hard to come by.

    RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults who recover in a week or two, according to the Centers for Disease Control and Prevention. But that’s not the case for infants and toddlers, who are at higher risk of the virus becoming severe or life-threatening.

    The first vaccine for RSV was approved in May and was targeted for older adults.

    Two months later, federal regulators approved the first long-lasting shot for infants younger than 8 months who are entering their first RSV season. According to the CDC, Nirsevimab, which is made by AstraZeneca and sold under the brand name Beyfortus, reduces the risk of severe RSV by 80%. One dose lasts about five months, the length of the average RSV season.

    The shot does not activate the immune system the way a vaccine would, but instead introduces antibodies to protect against RSV. Health officials with the CDC say once the antibodies are out of a baby’s system, the immunity is also gone.

    Amid the peak of RSV season, there has been unprecedented demand for the shot and not enough supplies to go around.

    The CDC recently announced the release of more than 77,000 additional doses to be distributed immediately to physicians and hospitals through the Vaccines for Children Program. The CDC and FDA are working with drug manufacturers to ensure availability through early next year.

    What preventive measures can parents can take?

    Children at high risk include those 6 months and younger, infants born prematurely, those younger than 2 with congenital heart disease and those with weakened immune systems who have neuromuscular disorders, according to the American Lung Assn.

    Previously, the only immunization against severe RSV for babies was a shot women could get during weeks 32 through 36 of pregnancy. That shot is still available and recommended September through January.

    There also are everyday preventive measures to help reduce the spread of RSV and other respiratory illnesses, according to health agencies such as the CDC, American Lung Assn. and the California Department of Public Health:

    • Stay home if you’re feeling sick.
    • If you need to leave your home, consider wearing a mask in crowded or indoor areas.
    • Wash your hands with soap and water for at least 20 seconds.
    • Avoid touching your face with unwashed hands.
    • Cover your mouth and nose when you cough and sneeze.
    • Avoid close contact with others, such as kissing, shaking hands and sharing cups and utensils.
    • Clean frequently touched surfaces, including doorknobs and mobile devices.

    What are the signs of RSV?

    RSV affects both the upper respiratory system, which includes the nose and throat, and the lower respiratory system, which includes the lungs.

    The virus is highly transmissible. You can catch it if the droplets from an infected person’s cough or sneeze get in your eyes, nose or mouth; if you touch a surface (such as a doorknob) that has the virus on it and then touch your face before washing your hands; or if you have direct contact with the virus (for example, by kissing the face of a child with RSV). Being in crowded places with people who may be infected or having exposure to other children or siblings who may be infected are common ways to pick up the virus.

    RSV can survive for many hours on hard surfaces such as tables and crib rails; it has a shorter life span on softer surfaces such as tissues and hands.

    A person infected with RSV is usually contagious for three to eight days. However, some infants and people with weakened immune systems can continue to spread the virus for as long as four weeks, even after their symptoms go away, according to the CDC.

    Virtually all children get an RSV infection by the time they are 2, but the virus can cause complications, the CDC said.

    Health agencies recommend parents reach out to their healthcare provider if their child is showing signs of infection.

    According to health officials at Cedars-Sinai Medical Center, the most common symptoms are runny nose; fever; cough; short periods without breathing; trouble eating, drinking or swallowing; wheezing, flaring of nostrils or straining of the chest or stomach while breathing; breathing faster than usual or trouble breathing; and turning blue around the lips and fingers.

    These symptoms can seem like other health conditions, so the hospital advises parents to have their child see a healthcare provider for a diagnosis.

    [ad_2]

    Karen Garcia

    Source link

  • L.A. County reports first flu death of season, renews call for residents to get vaccinated

    L.A. County reports first flu death of season, renews call for residents to get vaccinated

    [ad_1]

    Los Angeles County has confirmed its first flu death of the season, and with the bulk of the season still ahead, health officials are reminding residents to get vaccinated.

    The person who died was elderly and had multiple underlying health conditions, according to the county Department of Public Health. There was no record of the person being vaccinated for flu this season, officials added.

    “Although most people recover from influenza without complications, this death is a reminder that influenza can be a serious illness. … Annually, thousands of people nationwide are hospitalized or die from influenza-associated illness,” health officials said in a statement.

    Statewide, nine people have died from flu since Oct. 1, according to the latest data from the California Department of Public Health.

    Flu season usually runs from October through May and peaks around February, but every season is different. An estimated 670 Californians died from flu during the 2022-23 season, public health figures show.

    Federal health officials have long recommended most everyone get an annual flu shot. But that call has taken on increased urgency in recent years, given the additional threat posed by COVID-19 and respiratory syncytial virus, or RSV.

    Health officials are preparing for the possibility of a renewed “tripledemic” this winter, with all three viruses circulating widely at the same time. Last year, Southern California was hit hard by an early onslaught of RSV, a historically strong start to the flu season and a COVID-19 spike — straining a healthcare system already stretched thin and sending patients to the emergency room in droves.

    “Current indicators of influenza activity in Los Angeles County are in line with past seasons and have been rising in recent weeks,” officials said.

    As of the week that ended Nov. 4, the most recent period for which data are available, flu activity was still considered low statewide, according to the U.S. Centers for Disease Control and Prevention.

    But flu activity is increasing as the holiday season approaches, and officials largely recommend everyone age 6 months and older, especially older adults and those with weakened immune systems, get vaccinated.

    Although some healthy people may be unfazed by flu season, officials say they should still get the shot so they don’t spread the illness to someone who might not recover as quickly.

    [ad_2]

    Anthony De Leon

    Source link

  • Demand for RSV shot is so high, CDC is recommending it only for the most vulnerable

    Demand for RSV shot is so high, CDC is recommending it only for the most vulnerable

    [ad_1]

    Atlanta — Lucas Cerna’s mother is getting him a respiratory syncytial virus shot while his pediatrician still has it in stock.

    “I have just been seeing a lot in the news, and babies get really sick, so I was like, might as well just do it,” Cerna’s mother, Alexandra Perez, told CBS News. 

    The Beyfortus antibody shot, manufactured by drugmakers AstraZeneca and Sanofi, was approved by the Food and Drug Administration in July as a way to prevent RSV in infants and children up to 24 months old.

    Demand for the shot has been unprecedented. It is so popular, the U.S. Centers for Disease Control and Prevention is now recommending pediatricians like Dr. Jennifer Shu at Children’s Medical Group in Atlanta only give it to their most vulnerable patients, which includes infants younger than six months, and those with underlying conditions that put them at risk.

    “We’re hoping it’s going to really cut down in hospitalizations, as well as complications like pneumonia or even death,” said Shu, who added that in Georgia, cases are still rising and she is almost out of shots.

    Parts of the southern U.S. have been seeing a rise in RSV transmission in recent months, according to the CDC. Cook Children’s Medical Center in Fort Worth, Texas, reported Friday that more than 200 of its patients tested positive for RSV last week.

    Symptoms of RSV include a high fever, worsening cough and trouble breathing. The symptoms can lead to hospitalization and even death.

    “Their immune systems aren’t developed yet,” explained Shu on why infants are so vulnerable to RSV. “…The second thing is their airways are a little bit smaller.”

    Chris Comstock’s 20-month-old daughter Adilynn contracted RSV in September. She spent nine days fighting for her life in the Children’s Healthcare of Atlanta hospital. 

    “I just remember my wife and I were standing in the hospital room crying, going ‘What do you do?’” Comstock said. “I have zero control, sitting in that hospital room, knowing I can do nothing to help my child. And then watching her walk and run and get back to health again. You can’t put a price tag on the thankfulness that we have.”

    [ad_2]

    Source link

  • Flu And RSV Could Be On The Rise Nationwide

    Flu And RSV Could Be On The Rise Nationwide

    [ad_1]

    The Centers for Disease Control and Prevention reported on Friday that flu cases are low nationwide, but more could arise in the upcoming weeks.

    “Even these low levels will probably increase in the next couple of weeks,” said Alicia Budd, head of the CDC’s domestic influenza surveillance team, according to NBC News.

    The CDC report shows that by the end of last week, most states in the U.S. had low or minimal flu-related hospital visits. The CDC also has not detected an early rise in flu activity this year as it had last year, NBC News reported.

    But this week, the agency reported an increase in the number of respiratory illness-related hospitalizations. Between May 21 and Oct. 7, the percentage of hospital visits for respiratory illness increased for people ages 0 to 4 years old and 5 to 24 years old, and remained stable for other age groups, according to the CDC report.

    “Given what we saw last year, vaccinating kids is really important to prevent them from getting sick, prevent them from being hospitalized and having the most severe outcomes,” said Danielle Iuliano, senior research epidemiologist at the CDC, according to NBC News.

    The influenza virus is one of several viruses that contribute to respiratory illnesses, such as COVID-19 and respiratory syncytial virus, or RSV, according to the CDC.

    According to ABC News, COVID-19 hospitalizations consistently ticked up in recent months, but are now on the decline nationwide. A CDC spokesperson told HuffPost that RSV-related hospitalizations are increasing among infants, who are susceptible to the virus. Data from WastewaterSCAN indicates that influenza, COVID-19 and RSV are starting to spread at low levels.

    Many hospitals in New York, California and Massachusetts recently restored their mask mandates following the uptick in COVID-19 cases, The New York Times reported. The CDC is recommending that people 6 months and older get a flu shot and COVID-19 booster shot this fall. RSV vaccines are also available for older adults and those who are pregnant.

    [ad_2]

    Source link

  • RSV antibody shot for babies hits obstacles in rollout: “As pediatricians, we’re angry”

    RSV antibody shot for babies hits obstacles in rollout: “As pediatricians, we’re angry”

    [ad_1]

    RSV season is ramping up, and doctors are hoping a new shot to prevent the virus in young children will ease the caseload this year. However, some pediatricians are facing challenges getting supply.  

    The CDC and FDA have approved the Beyfortus antibody shot, from drugmakers AstraZeneca and Sanofi, to prevent respiratory syncytial virus in babies from birth to 8 months old, or in children up to 24 months old with severe risk factors.    

    RSV is the leading cause of hospital admissions in children younger than 1 year old. 

    Dr. Lauren Fitzpatrick, the medical director of the pediatric unit at Luminis Health Anne Arundel Medical Center, says pediatricians were optimistic the drug could help reduce cases after a record year in 2022.

    “We thought that this was groundbreaking, that this could be our game-changer, that we could potentially really reduce the risk of patients being admitted for RSV,” she told CBS News. I think there was our hopes, and then there was our reality,” 

    “There was not an infrastructure in place to roll out this vaccine, or monoclonal antibodies, so even though we have families that are requesting it, we can’t meet their demands.” 

    A big complication right now is the cost, at nearly $500 a dose. While the shot is expected to be covered by most insurance plans, providers have to order supplies before knowing how much they’ll be reimbursed.  

    “As pediatricians, we’re angry,” Fitzpatrick said. “It feels like we have an opportunity that may be missed.”  

    And as a mom, Fitzpatrick knows firsthand how important this shot is. Her youngest, now 5, struggled with RSV at 9 months old.

    “It was a very hard time,” she said. “I don’t want this to be dollars and cents. This is my kid’s life. But for a lot of the insurance companies, it’s dollars and cents.”

    Earlier in the summer, the American Academy of Pediatrics sent a letter to the CDC and the Centers for Medicare and Medicaid Services urging federal leaders to make sure the shot could be distributed widely and equitably.  

    The CDC recently announced pediatricians will be able to get paid for counseling families about the drug in addition to administering the product.  

    Fitzpatrick says she would also like to see insurance companies provide more clarity on how they will cover the expensive shot.  

    “These are small practices that don’t have that type of capital to invest,” she explained. “If there were some type of plan in place that the insurance companies could work with the practices to either expedite their reimbursement or provide some funding ahead of time, that would be helpful.”

    Molly Fleenor, who is expecting her second daughter in December, the peak of RSV season, says she hopes the confusion is resolved by then.  

    “It shouldn’t be a guessing game,” Fleenor said. “It should be pretty black-and-white and should be accessible and available to as many people as possible, if not everybody.”  

    Fleenor will also be eligible for the new RSV vaccine for pregnant women in their third trimester, to help protect her baby. 

    Doctors are recommending either that shot for mom or the immunization for the newborn. Fleenor is still deciding between the two, but knows she wants the protection.  

    “RSV can be very scary,” she said. “It can take a turn really quickly and make children really sick.”  

    The American Academy of Pediatrics recommends that all infants whose mothers did not receive the maternal vaccine receive the new preventive antibody, especially those at high risk for RSV.  

    [ad_2]

    Source link

  • CDC recommends Pfizer’s RSV vaccine during pregnancy as protection for newborns

    CDC recommends Pfizer’s RSV vaccine during pregnancy as protection for newborns

    [ad_1]

    An advisory panel for the U.S. Centers of Disease Control and Prevention on Friday recommended that a vaccine for respiratory syncytial virus, or RSV, be given during pregnancy, providing an extra level of protection for newborns against the disease.

    The panel recommended in an 11-1 vote that Pfizer’s Abrysvo be given during weeks 32 to 36 of pregnancy. The recommendation was formally adopted by CDC Director Dr. Mandy Cohen.

    Abrysvo was approved by the Food and Drug Administration for administration to pregnant people last month but needed the CDC’s approval as well before it could be added to a list of “maternal vaccines” recommended before birth.

    This also comes after both the FDA and CDC earlier this summer approved nirsevimab, an RSV antibody injection, for infants and young children.

    Nirsevimab, manufactured by Sanofi and AstraZeneca and sold under the brand name Beyfortus, has been found to prevent “severe RSV disease,” the CDC said. It is meant to be administered just before or during the RSV season, which runs from October to March.

    RSV is the leading cause of hospitalization among infants, according to the CDC.

    “I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth,” Cohen in a statement Friday.

    In June, the CDC gave its approval to both Abrysvo and GSK’s Arexvy vaccine as protections against RSV for adults ages 60 and older.

    The previous month, Arexvy became the first RSV vaccine to ever receive approval from the FDA.  

    According to the CDC, anywhere from 58,000 to 80,000 children under the age of 5 are hospitalized with RSV every year in the U.S., while between 60,000 and 160,000 people over the age of 65 are hospitalized annually with the disease.

    Alex Tin contributed to this report.

    [ad_2]

    Source link